home / stock / scnlf / scnlf quote
Last: | $0.127 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.127 |
High: | $0 |
Low: | $0 |
Volume: | 22,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.127 | $0 | $0.127 | $0 | $0 | 22,000 | 05-03-2024 |
$0.127 | $0.127 | $0.127 | $0.127 | $0.127 | 1,500 | 01-10-2024 |
$0.132 | $0.132 | $0.132 | $0.132 | $0.132 | 40,000 | 12-01-2023 |
$0.166 | $0.166 | $0.166 | $0.166 | $0.166 | 5,000 | 09-19-2023 |
$0.15 | $0.15 | $0.15 | $0.15 | $0.15 | 5,000 | 08-14-2023 |
$0.166 | $0.1562 | $0.166 | $0.166 | $0.1562 | 22,500 | 08-10-2023 |
$0.174 | $0.174 | $0.174 | $0.174 | $0.174 | 500 | 06-26-2023 |
$0.195 | $0.195 | $0.195 | $0.195 | $0.195 | 22,000 | 06-20-2023 |
$0.22 | $0.22 | $0.22 | $0.22 | $0.22 | 100 | 02-16-2023 |
$0.53 | $0.58715 | $0.53 | $0.58715 | $0.53 | 12,650 | 02-15-2023 |
$0.5317 | $0.5317 | $0.5317 | $0.5317 | $0.5317 | 100 | 02-13-2023 |
$0.4 | $0.4 | $0.4 | $0.4 | $0.4 | 100 | 01-25-2023 |
$0.29 | $0.29 | $0.29 | $0.29 | $0.29 | 350 | 01-10-2023 |
$0.16 | $0.16 | $0.16 | $0.16 | $0.16 | 100 | 11-01-2022 |
$0.1 | $0.1 | $0.1 | $0.1 | $0.1 | 100 | 08-15-2022 |
$0.18 | $0 | $0.18 | $0 | $0 | 50 | 08-09-2022 |
$0.18 | $0.18 | $0.18 | $0.18 | $0.18 | 15,450 | 07-28-2022 |
$0.151 | $0.151 | $0.151 | $0.151 | $0.151 | 10,000 | 06-13-2022 |
$0.17 | $0.17 | $0.17 | $0.17 | $0.17 | 10,000 | 05-02-2022 |
$0.0311 | $0.031055 | $0.0311 | $0.0311 | $0.0311 | 535 | 03-29-2022 |
News, Short Squeeze, Breakout and More Instantly...
Scancell Holdings Plc Ord Company Name:
SCNLF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durra...
(NewsDirect) Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the clinical stage biopharmaceutical company's progress and financial position. Durrant starts by highlighting that Scancel...